Ramucirumab/Erlotinib Approved: Metastatic Non-Small Cell Lung Cancer

The FDA has approved ramucirumab (Cyramza®, Eli Lilly and Company) in combination with erlotinib for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 substitution mutation. The approval was based on RELAY (NCT02411448), a phase 3 trial that enrolled 449 patients with untreated stage IV NSCLC. Eligible patients were at least 18 years old, had an Eastern Cooperative Oncology Group (ECOG) perfo...
Continue reading

Ramucirumab/Docetaxel Significantly Improves PFS, Not OS, in Urothelial Carcinoma

In previous studies, ramucirumab plus docetaxel has been shown to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. To add to this research, investigators conducted a study to determine overall survival results of ramucirumab/docetaxel after receiving platinum-based therapy. In this randomized, double-blind, phase 3 trial, 530 patients with advanced or metastatic urothelial carcinoma who experienced disease progression during or after platinum-based chemoth...
Continue reading

FDA Approves Ramucirumab for Advanced Hepatocellular Carcinoma

Based on REACH-2, a phase 3 trial, ramucirumab (Cyramza®, Eli Lilly) was granted FDA approval for patients with advanced hepatocellular carcinoma, a-fetoprotein concentrations of ≥400 ng/mL, and who have been previously treated with sorafenib. Ramucirumab had already been FDA approved for treatment of advanced gastric cancer, non-small cell lung cancer, and metastatic colorectal cancer. This drug works as a monoclonal antibody that targets and binds to the vascular endothelial growth factor rece...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.